In October of 2018, InEK has published the list of the devices, previously (in 2018) eligible for innovation funding via NUB (received status 1), and which will be integrated into DRG payment system since 2019. Only two devices will be transferred into the DRG catalogue:
- Radionuclide therapy with Lutetium 177-labeled prostate-specific membrane antigen (PSMA) in prostate cancer – treatment will be reimbursed via DRG M10B “Radioligandentherapie mit Lutetium-177-PSMA-Liganden”
- Percutaneous mitral valve anullorrhopathy with clasp (was applicable to devices like Carillon from Cardiac Dimensions) – device will be reimbursed via DRG F98C “Komplexe minimalinvasive Operationen an Herzklappen ohne minimalinvasiven Eingriff an mehreren Herzklappen [...] ohne sehr komplexen Eingriff”
See full details in German here.
Subscribe to our newsletter delivered every second week not to miss important reimbursement information.